Matthew Boyd

It’s time for the November edition of our MedTech Startup Spotlight series!  With the growing pipeline of startups from Rhode Island's developing life sciences ecosystem, we’d like to highlight a local company focusing on another aspect of patient care. Meet Docs for Health–a Rhode Island-based startup that addresses the social needs of patients in real-time by partnering with hospitals, clinics, and payors to treat the social determinants of health. With intervention being the key ingredient of this unique approach, the impact on a patient’s life is nearly 17x that of one of the most common drugs used in medicine today.  Read on to learn how Docs for Health is shifting the paradigm of the standard of care for patients. “because healthcare involves more than medicine…” Read the full blog here: https://lnkd.in/e5qEbTRP Rahul Vanjani James Lawless, LMHC #DocsForHealth #SDoH #SocialDeterminantsofHealth #NEMIC #StartupSpotlight #RhodeIsland  #SmallBusiness #Healthcare

11

Have you listened to the Funding Medtech Podcast from Project Medtech? As always, this is a great resource to add to your medtech toolkit. The Funding Medtech series is "focused on exploring ways to fund Medtech innovation through dilutive and non-dilutive capital." https://lnkd.in/eW8FKWSS #medtech #ProjectMedtech #funding

4

This episode of Marney's Minutes is a topic I get asked a lot about, since I spent 4.5 years in an industry leading MedTech company bringing on and developing HCPs (surgeon consultants) and then 4 years in an industry leading ASC company creating educational programs and once again, working with HCPs. This is part of a series for surgeons who are looking to start their consulting careers with MedTech companies, or who are looking to increase their current engagement with their industry partners. https://lnkd.in/ej5H8tqH #Orthopaedics #SurgeonConsultant #Healthcare #MedTech #ConsultingWithIndustry #MarneyReid

7

🤕 The U.S. market for advanced wound dressings is evolving rapidly, driven by innovation and an aging population. Understanding the nuances of this growing sector is crucial for medtech companies looking to capitalize on new opportunities. Check out our latest article with Med Device Online to learn more about the latest trends, challenges, and market drivers shaping the future of advanced wound care. 🔗: https://lnkd.in/gYsCBB_5 #MedTech #AdvancedWoundCare #HealthcareInnovation #MedicalDevices #WoundDressings #MarketTrends #MarketIntelligence #MarketResearch #iDataResearch

1

Stallergenes Greer participated in the ACAAI 2024 Annual Scientific Meeting in Boston, MA, October 25-28 and had the opportunity to sponsor a (non-CME) Product Theater. "Peanut Allergy in Toddlers: A New FDA Approved Treatment" was presented by James R. Baker, Jr., MD, Mary H. Weiser Food Allergy Center at Michigan Medicine and Stephen Tilles, MD, University of Washington, Consultant for Stallergenes Greer and moderated by Anne-Marie Irani, MD, Virginia Commonwealth University, Consultant for Stallergenes Greer. The presentation reviewed the unmet needs of peanut allergy in the toddler age group (1 through 3) and the evidence supporting the early intervention for food allergy, including peanut, as well as the safety and efficacy of oral immunotherapy in toddlers and the changes in biomarkers seen during the POSEIDON clinical trial.[1] Tibor Nemes, Head of Americas states “I am pleased with the excitement of attendees around the expanded indication to include ages 1 through 3 and the interest to integrate Palforzia® into their practices." Palforzia® [Peanut (𝘈𝘳𝘢𝘤𝘩𝘪𝘴 𝘩𝘺𝘱𝘰𝘨𝘢𝘦𝘢) Allergen Powder-dnfp] is the only U.S. Food and Drug Administration (FDA) approved oral immunotherapy treatment (OIT) for peanut allergy in ages 1 through 17 years, for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.[1] The Product Theater content and views expressed therein do not necessarily reflect the views, position or policies of the American College of Allergy, Asthma and Immunology. Speakers have been compensated. --- [1] See full prescribing information, including Boxed WARNING, and Medication Guide at www.PalforziaPRO.com.

181

2 Comments

In a recent MedTech Insight article, Click CEO David Benshoof Klein and CMO Shaheen E Lakhan, MD, PhD, FAAN highlighted Click's strategic priorities, new developments in our pipeline, and the transformative potential of the FDA's latest Prescription Drug Use-Related Software (PDURS) draft guidance on #DigitalTherapeutics. Insights included: - The FDA’s “Prescription Drug Use-Related Software” draft guidance represents a pivotal opportunity for Click, as it helps clarify how combining our software as a medical device (#SaMD) with pharmacotherapy could enable pharma manufacturers to update drug labels with additional clinically meaningful benefit claims. - Leveraging digital interventions to offer personalized treatment not only improves outcomes across various health metrics like cognitive function and cardiovascular risk but also aligns with pharma's evolving demand for tailored solutions, potentially reshaping patient management and payer agreements, particularly in the GLP-1 therapy space. - Click continues to thrive by prioritizing rigorous clinical trials and demonstrating substantial clinical benefits, contrasting with competitors who faced challenges in meeting stakeholder expectations. Read more about Click's approach and our views on the future of digital therapeutics here: https://lnkd.in/epPgkPF9 #DTx #HealthInnovation #MedicalTechnology #ClinicalResearch

66

2 Comments

📍You are invited to join the Ori team in Boston to experience IRO® - the New Standard of CGT Manufacturing On September 17th join us, Jason C. Foster, Ori Biotech CEO and Matthew Hewitt, Vice President, CTO Manufacturing at Charles River Laboratories for an evening with IRO, where we'll be showcasing: 🔹 New real-world data from the platform 🔹 In-person IRO demos If you'd like to see an IRO in-person (trust us, you do!) and dive into the data – showing how it automates better biology, accelerates product development and helps to scale your impact, secure your place today ➡️ https://lnkd.in/ep6p_DZ3 #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

21

💡 Stuart Sundem's latest article on our site is a great reminder of how market research saves money and creates value, making it essential even when budgets are lean. Click through to the post for the full article, and let us know what you think - do you agree? #MedTech #MarketResearch #ProductDevelopment

4

💡 Venture capital investment drove total deal value to $3.3 billion in the first quarter of 2024, the highest level since the fourth quarter of 2022, according to the PitchBook report. Read more: https://lnkd.in/gD4jwEj5 #financialtimes #investing #financeandeconomy #capitalraising #businessandmanagement #capital #startupstrategies #biopharma #biopharmaceuticals #pharma #technology #biopharmaceuticals #biopharma #investment #innovation #innovationinhealthcare #mna #mergersandacquisitions #biology #startup #diagnostics #diagnostictesting #medicaldevices #medicaldevice #digitisation #digitaltransformation #digitalhealth #digitalcare #vaccination #medicaldeviceinnovation #medical #healthtech #wereabletechnology #futureofhealthcare #digitalhealth #breatcancerawareness #imagingtechnologies #imaging #medtech #artificialintelligence #ai #digitaltherapeutics #digitalhealth #healthtech #sustainabilityinhealthcare #healthcareinnovation #Switzerland #funding #investmentopportunities #investmentstrategy #investmentresearch #biotechinvesting #medtechinvesting #healthtech

11

BIG NEWS! Genezen has signed an agreement to acquire uniQure’s commercial gene therapy manufacturing operations in Lexington, Massachusetts. This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Steve Favaloro, President and Chief Executive Officer of Genezen, commented, “...This acquisition significantly enhances Genezen’s scale and differentiated capabilities, directly aligned with our mission to advance cell and gene therapies by providing top-tier, science-driven development and manufacturing solutions. We are honored to deliver these services to our current customers and the patients they serve, and are well positioned to immediately extend our support to even more customers in Lexington.” #cdmo #viralvectors #cellandgenetherapy #celltherapy #genetherapy #precisionmedicine #mergersandacquisitions #investment #finance #pharma #biotech CSL Ampersand Capital Partners https://lnkd.in/eqDDc_cf

194

15 Comments

It always starts with leadership.   Striving to be the boldest medtech company on the planet. Go big.   Advancing technology, to the patient, surgeon provider, and all of the stakeholders in the healthcare continuum   Progressive leadership and Force Multipliers tend to be attracted to joining teams that choose to have the biggest impact and how can they solve the largest problems.   Can you impact at a massive scale?   Go do it.   Full session in Comments Mark Bezjak Joe Urban Ivan Tornos Zimmer Biomet

39

3 Comments

FDA is considering redesigning its device and diagnostics premarket review process to improve expectations, ensure better first-time submissions, and allow more flexibility in the review process, according to Jeff Shuren, director of the Center for Devices and Radiological Health. The objective would be to reduce the number of deficiency letters and complete more reviews in a single cycle. Ferdous Al-Faruque reports in Regulatory Focus 🖊️✅ https://bit.ly/444CVC0

82

#ICYMI -- watch our CEO, Pete Carlson talk the use of #ai in our DeepView technology for wound healing prediction at Benzinga virtual event last week. Full recap -> https://lnkd.in/e2jUYuzK #Benzinga #burninjuries #woundhealing #predictiveai

42

💡 Simplifying CAR-T workflows will help to break down barriers to patient access Tune into our new episode of the Ori Spotlight Podcast, where Boro Dropulićć, CEO of Vector BioMed, Inc. and Executive Director at Caring Cross, joins Ori CEO Jason C. Foster for a conversation on how decentralized, point-of-care models and open-source workflows are transforming CGT manufacturing. Boro and Jason discuss how low-cost vector production and new manufacturing processes are key to expanding global access to CAR-T therapies, and delve into the role of digital technologies and partnerships in driving down the costs of gene therapies while maintaining GMP quality. Listen now ➡️ https://lnkd.in/eZdT6krq #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

47

3 Comments

TODAY on The Leading Difference podcast: Mark Oreschnick, a MedTech industry leader and the founder of Evolve Engineering, shares his journey of nearly 30 years in engineering and leadership, starting in aerospace before landing in the medical device industry. With a passion for mentoring and helping startups, Mark discusses the importance of right-sizing staff and systems for success. This conversation not only showcases the human side of technology, but also highlights the power of networking and building relationships for personal and professional growth.: https://hubs.li/Q02jH3KQ0.

9

2 Comments

Fueling Your Medtech Innovation with Smart Funding Having a bold medtech idea is just the start. Securing the right funding to bring it to life? That’s where we come in. At Merge | Medical Device Studio, we simplify medtech funding with strategies that fit your vision. Here’s how we help early-stage innovators: ·      Funding options: From grants to strategics, we guide you to the best fit  ·      Investor pitch: Craft a clear, compelling story that makes you stand out ·      Smart financial models: Show how your idea scales and thrives long-term 💡 Let’s turn your idea into reality. Ready to secure the funding you need? #MedTech #Innovation #Funding #MergeMed #StartupSuccess

5